Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

Onxeo SA engages in the development of drugs for the treatment of cancer. The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP. It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad. The company was... 
09/10Earnings Call
Surperformance© rating of BioAlliance Pharma SA
Trading Rating : - Investor Rating :
More about the company
Financials (€)
Sales 2014 17,1 M
EBIT 2014 -1,82 M
Net income 2014 -1,66 M
Finance 2014 37,0 M
Yield 2014 -
Sales 2015 5,02 M
EBIT 2015 -15,0 M
Net income 2015 -15,6 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 9,31x
Capi. / Sales 2015 39,1x
Capitalization 196 M
More Financials
08/06 BIOALLIANCE PHARMA : Data on Dermatology Drugs Detailed by Researchers at BioAll..
07/29 BIOALLIANCE PHARMA : Partner Innocutis Introduces Sitavig in U.S.
07/28 TOPOTARGET A/S : BioAlliance Pharma and Topotarget: Cross-Border Merger Now lega..
07/28 TOPOTARGET A/S : BioAlliance Pharma and Topotarget Confirm Cross-border Merger
07/24 BIOALLIANCE PHARMA : Partner Innocutis Launches Sitavig in U.S.
07/24 BIOALLIANCE PHARMA : Introduces Sitavig in the U.S. by Partner Innocutis
07/09 BIOALLIANCE PHARMA : FDA approval of Beleodaq™ belinostat
05/22 BIOALLIANCE PHARMA : Livatag Gets FDA Fast Track Designation for Treatment of Pr..
05/22 BIOALLIANCE PHARMA : Livatag Given Fast Track Designation by the FDA for the Tre..
05/21 BIOALLIANCE PHARMA : Definitive Merger Plan between BioAlliance Pharma and Topot..
04/25 BIOALLIANCE PHARMA : Updates on a New Positive DSMB Recommendation to Continue I..
04/23 BIOALLIANCE PHARMA : DSMB Recommends Continuation of Phase III Clinical Trial
More news
Income Statement Evolution
BioAlliance Pharma SA : Income Statement Evolution
More Financials
EPS Revisions
BioAlliance Pharma SA : EPS Revisions
More Estimates Revisions
Dynamic quotes